Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis

Table 5 Univariate and multivariate analyses of clinical variables on overall survival

	Univariate HR (95% CI)	P	Multivariate HR (95% CI)	P
Age (≥60/< 60)	1.17 (0.58–2.36)	0.667
Gender (Female/Male)	0.61 (0.29–1.23)	0.158
Smoking status (Smoking/Never)	1.61 (0.74–3.51)	0.225
KPS (≥80/< 80)	0.39 (0.19–0.84)	0.012	0.43 (0.19–0.94)	0.034
EGFR mutation (exon 19 deletion/exon 21 L858R)	0.79 (0.39–1.58)	0.495
Co-existing BMs (yes/no)	0.57 (0.22–1.51)	0.25
Intracranial symptoms (yes/no)	1.31 (0.54–3.17)	0.554
LM at the time of NSCLC diagnosis (yes/no)	0.35 (0.11–1.14)	0.066
Treatment for LM
WBRT (yes/no)	0.45 (0.23–0.91)	0.022	0.49 (0.24–1.01)	0.54
EGFR-TKIs (yes/no)	0.31 (0.15–0.67)	0.002	0.26 (0.11–0.58)	0.001
WBRT+EGFR-TKIs/EGFR-TKIs alone	0.68 (0.29–1.61)	0.381

LM Leptomeningeal metastasis, KPS Karnofsky performance status, NSCLC Non-small-cell lung cancer, EGFR Epidermal growth factor receptor, TKI Tyrosine kinase inhibitor, WBRT Whole brain radiotherapy, ChT Chemotherapy, BMs Brain metastases

ISSN: 1748-717X